Overview

Alemtuzumab and CHOP in T-cell Lymphoma

Status:
Completed

Trial end date:
2016-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

Aarhus University Hospital

Collaborator:

GCP-unit at Aarhus University Hospital, Aarhus, Denmark

Treatments:

Alemtuzumab
Cyclophosphamide
Doxorubicin
Lenograstim
Liposomal doxorubicin
Vincristine